268 related articles for article (PubMed ID: 23688836)
1. Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases.
Salvador JA; Pinto RM; Silvestre SM
J Steroid Biochem Mol Biol; 2013 Sep; 137():199-222. PubMed ID: 23688836
[TBL] [Abstract][Full Text] [Related]
2. An overview on 5alpha-reductase inhibitors.
Aggarwal S; Thareja S; Verma A; Bhardwaj TR; Kumar M
Steroids; 2010 Feb; 75(2):109-53. PubMed ID: 19879888
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer.
Njar VC; Brodie AM
Curr Pharm Des; 1999 Mar; 5(3):163-80. PubMed ID: 10066888
[TBL] [Abstract][Full Text] [Related]
4. Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer.
Schmidt LJ; Tindall DJ
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):32-8. PubMed ID: 20883781
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
[TBL] [Abstract][Full Text] [Related]
6. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
Rafferty SW; Eisner JR; Moore WR; Schotzinger RJ; Hoekstra WJ
Bioorg Med Chem Lett; 2014 Jun; 24(11):2444-7. PubMed ID: 24775307
[TBL] [Abstract][Full Text] [Related]
7. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.
Grigoryev DN; Long BJ; Nnane IP; Njar VC; Liu Y; Brodie AM
Br J Cancer; 1999 Oct; 81(4):622-30. PubMed ID: 10574247
[TBL] [Abstract][Full Text] [Related]
8. CYP17 inhibitors for prostate cancer therapy.
Vasaitis TS; Bruno RD; Njar VC
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):23-31. PubMed ID: 21092758
[TBL] [Abstract][Full Text] [Related]
9. CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
Yin L; Hu Q
Nat Rev Urol; 2014 Jan; 11(1):32-42. PubMed ID: 24276076
[TBL] [Abstract][Full Text] [Related]
10. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Bird IM; Abbott DH
J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
[TBL] [Abstract][Full Text] [Related]
11. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
Pinto-Bazurco Mendieta MA; Negri M; Jagusch C; Müller-Vieira U; Lauterbach T; Hartmann RW
J Med Chem; 2008 Aug; 51(16):5009-18. PubMed ID: 18672868
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, 17α-hydroxylase-C
Banday AH; Shameem SA; Banday JA; Ganaie BA
Anticancer Agents Med Chem; 2018; 18(13):1919-1926. PubMed ID: 29697032
[TBL] [Abstract][Full Text] [Related]
14. A review on steroidal 5α-reductase inhibitors for treatment of benign prostatic hyperplasia.
Sun J; Xiang H; Yang LL; Chen JB
Curr Med Chem; 2011; 18(23):3576-89. PubMed ID: 21756226
[TBL] [Abstract][Full Text] [Related]
15. Targeting CYP17: established and novel approaches in prostate cancer.
Yap TA; Carden CP; Attard G; de Bono JS
Curr Opin Pharmacol; 2008 Aug; 8(4):449-57. PubMed ID: 18619560
[TBL] [Abstract][Full Text] [Related]
16. Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II.
Pais P
Adv Ther; 2010 Aug; 27(8):555-63. PubMed ID: 20623347
[TBL] [Abstract][Full Text] [Related]
17. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Rittmaster RS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
[TBL] [Abstract][Full Text] [Related]
18. Role of 5α-reductase inhibitors in benign prostatic diseases.
Azzouni F; Mohler J
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):222-30. PubMed ID: 22333687
[TBL] [Abstract][Full Text] [Related]
19. 17alpha-hydroxylase/17,20-lyase (p450(17alpha)) inhibitors in the treatment of prostate cancer: a review.
Owen CP
Anticancer Agents Med Chem; 2009 Jul; 9(6):613-26. PubMed ID: 19601745
[TBL] [Abstract][Full Text] [Related]
20. Dutasteride for the treatment of prostate-related conditions.
Slater S; Dumas C; Bubley G
Expert Opin Drug Saf; 2012 Mar; 11(2):325-30. PubMed ID: 22316171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]